Johnson & Johnson said it has completed its acquisition of Halda Therapeutics OpCo, Inc., bringing the clinical-stage biotechnology company and its proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC) platform into the company for $3.05 billion in cash.
The deal adds HLD-0915, Halda’s clinical-stage prostate cancer therapy, to Johnson & Johnson’s oncology portfolio. The company described HLD-0915 as a once-daily oral treatment that uses the RIPTAC™ platform to enable a precision, tumor cell-killing approach designed to address mechanisms of treatment resistance in prostate cancer.
Beyond the lead program, Johnson & Johnson said the acquisition includes several earlier-stage RIPTAC™-based candidates across additional solid tumors, including breast and lung cancer, and positioned the platform as a potential engine for next-generation oral targeted therapies in oncology and possibly other disease areas.
Johnson & Johnson said the acquisition will be accounted for as a business combination. With the transaction closing in 2025, the company expects dilution to adjusted earnings per share in the fourth quarter of 2025 and in 2026, with total adjusted EPS dilution of approximately $0.20 expected to be split evenly between the two years based on current estimates tied to non-recurring charges related to Halda employee equity awards, financing, and integration costs. The company said it plans to provide commentary on full-year 2026 guidance during its fourth-quarter earnings call scheduled for Wednesday, January 21, 2026.
KEY QUOTES:
“This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines. We are excited to formally welcome the talented Halda team to Johnson & Johnson and look forward to working together to achieve our shared goal of eliminating cancer.”
Jennifer Taubert
“Now that we have finalized this acquisition, we will focus on advancing the potential of this promising pipeline of novel product candidates and harnessing the powerful RIPTAC™ platform to discover more molecules in oncology and beyond.”
John C. Reed, M.D., Ph.D.
